ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.686,60
1,07%
S&P 500
5.214,08
0,51%
Dow Jones
39.387,76
0,85%
Euro vs US Dollar
1,07757
-0,05%
Bitcoin
62.842,68
-0,32%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Lipocine Inc (LPCN)

  7. Lipocine Inc (LPCN) News

LPCN

Lipocine (LPCN)

Lipocine Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:LPCN
DatumZeitQuelleÜberschriftSymbolFirma
09/05/202414h00PR Newswire (US)Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024NASDAQ:LPCNLipocine Inc
09/05/202412h06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LPCNLipocine Inc
09/05/202412h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
08/05/202414h00PR Newswire (US)Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024NASDAQ:LPCNLipocine Inc
08/05/202412h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
01/05/202414h00PR Newswire (US)Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154NASDAQ:LPCNLipocine Inc
11/04/202413h00PR Newswire (US)Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with ObesityNASDAQ:LPCNLipocine Inc
28/03/202413h00PR Newswire (US)Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with CirrhosisNASDAQ:LPCNLipocine Inc
25/03/202413h00PR Newswire (US)Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154NASDAQ:LPCNLipocine Inc
07/03/202423h31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
07/03/202414h00PR Newswire (US)Lipocine Announces Financial Results for the Full Year Ended December 31, 2023NASDAQ:LPCNLipocine Inc
07/03/202412h08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
07/03/202412h07Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:LPCNLipocine Inc
06/03/202414h00PR Newswire (US)Lipocine to Present at 36th Annual Roth ConferenceNASDAQ:LPCNLipocine Inc
06/03/202412h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
12/02/202422h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
06/02/202414h00PR Newswire (US)Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154NASDAQ:LPCNLipocine Inc
02/02/202414h00PR Newswire (US)Lipocine Announces Continued Commercialization of TLANDO® through Verity PharmaceuticalsNASDAQ:LPCNLipocine Inc
18/01/202414h20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
18/01/202414h00PR Newswire (US)Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and CanadaNASDAQ:LPCNLipocine Inc
19/12/202316h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
19/12/202314h00PR Newswire (US)Lipocine to Present at Biotech Showcase 2024NASDAQ:LPCNLipocine Inc
22/11/202322h15Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:LPCNLipocine Inc
13/11/202320h45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
13/11/202320h45PR Newswire (US)Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023NASDAQ:LPCNLipocine Inc
08/11/202319h15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LPCNLipocine Inc
08/11/202315h50Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
08/11/202314h00PR Newswire (US)Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023NASDAQ:LPCNLipocine Inc
01/11/202314h31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
01/11/202313h00PR Newswire (US)Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023NASDAQ:LPCNLipocine Inc
 Showing the most relevant articles for your search:NASDAQ:LPCN

Kürzlich von Ihnen besucht

NYSE
NKE
Nike
NYSE
KO
Coca Cola
USOTC
BNPQY
BNP Paribas (QX)
AMEX
XLV
Health Care Select Sector
TG
NOV
Novo Nordisk
TG
MBG
MercedesBenz
USOTC
DTEGY
Deutsche Telekom (QX)
DBI
TDXP
Tec DAX
PM
XAUUSD
Gold vs US Dollar
NASDAQ
MSFT
Microsoft
NASDAQ
QQQ
Invesco QQQ Trust Series 1
AMEX
SPY
SPDR S&P 500
CCOM
SILVER
SILVER
TG
432
Arbor Metals
CCOM
US100
US Tech 100
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten